These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32884987)

  • 1. Targeting angiogenesis for liver cancer: Past, present, and future.
    Zhu XD; Tang ZY; Sun HC
    Genes Dis; 2020 Sep; 7(3):328-335. PubMed ID: 32884987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects.
    Zhu XD; Li KS; Sun HC
    Genes Dis; 2020 Sep; 7(3):359-369. PubMed ID: 32884990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging agents and regimens for hepatocellular carcinoma.
    Zhu XD; Sun HC
    J Hematol Oncol; 2019 Oct; 12(1):110. PubMed ID: 31655607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment options for hepatocellular carcinoma.
    Eugen K
    Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
    Trojan J; Waidmann O
    J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.
    Kudo M
    Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30380773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
    Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
    J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
    Ghaziani TT; Dhanasekaran R
    Curr Treat Options Gastroenterol; 2021 Jun; 19(2):351-368. PubMed ID: 35530750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.